20-F: Zhengye Biotechnology Reports Significant Revenue Decline

Zhengye Biotechnology Holding Limited's Form 20-F filing reveals a substantial revenue decrease in fiscal year 2025, primarily attributed to a downturn in the hog market and strategic sales adjustments.

Summary

• Zhengye Biotechnology Holding Limited filed its Form 20-F for the fiscal year ended December 31, 2025.
• The company experienced a significant revenue decline of 37.6% in 2025, falling to RMB116.4 million (US$16.6 million) from RMB186.4 million in 2024.
• This decline is primarily attributed to a downturn in the hog market, characterized by low and volatile prices, which reduced demand for swine vaccines.
• Government policies aimed at reducing sow inventory also contributed to lower demand for swine vaccines.
• The company's operating loss widened to RMB70.5 million (US$10.1 million) in 2025, compared to an operating income of RMB16.4 million in 2024.
• Consequently, the net loss for 2025 was RMB83.0 million (US$11.9 million), a significant shift from a net income of RMB13.5 million in 2024.
• The company is also undergoing a share reclassification and consolidation, with a dual-class share structure approved on March 24, 2026.
• The company's R&D expenses increased by 40.8% in 2025 to RMB18.0 million (US$2.6 million) as it focuses on developing new products and expanding into the household animal vaccines market.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the significant revenue decline, net loss, and identified material weakness in internal controls, despite strategic efforts in R&D and market expansion.

Positives

• The company is expanding its product portfolio by developing vaccines for household animals, including a Rabies Vaccine for dogs and is in the process of registering feline and canine vaccines.
• The company has a diversified product portfolio with 50 veterinary vaccines covering major livestock, and is also developing vaccines for household animals.
• Zhengye Biotechnology maintains high production quality, with three veterinary vaccine production floors and 13 production lines operating in accordance with Good Manufacturing Practices (GMP) and ISO standards.
• The company has strong research and development capabilities with 51 employees in its R&D department and collaborations with several universities and research institutions.
• The company has an extensive distribution network, selling products in 29 provincial regions across China and exporting to Vietnam, Pakistan, and Egypt.
• The company has obtained a broad range of regulatory approvals for its products in China.
• The company has a plan to advance merger and acquisition initiatives in 2026, with a strategic focus on the pet sector.

Negatives

• Revenue decreased by 37.6% in 2025 to RMB116.4 million (US$16.6 million) from RMB186.4 million in 2024.
• The company reported a net loss of RMB83.0 million (US$11.9 million) for the year ended December 31, 2025, compared to a net income of RMB13.5 million in 2024.
• Gross profit decreased significantly from RMB91.3 million in 2024 to RMB23.9 million (US$3.4 million) in 2025, with the gross profit margin falling from 49.0% to 20.5%.
• Total operating expenses increased from RMB74.9 million in 2024 to RMB94.4 million (US$13.5 million) in 2025.
• The company's largest customer's demand for swine vaccines dropped significantly, leading to a substantial decrease in revenue from this customer.
• The company has a material weakness in its internal control over financial reporting due to a lack of accounting staff and resources with appropriate knowledge of U.S. GAAP and SEC reporting requirements.
• The company does not intend to pay dividends in the foreseeable future.

Risks

• The company faces significant risks related to doing business in China, including potential changes in government policies, uncertainties in the interpretation and enforcement of PRC laws and regulations, and difficulties in effecting service of legal process or enforcing foreign judgments.
• Greater oversight by the Cyberspace Administration of China (CAC) over data security, particularly for companies seeking to list on foreign exchanges, could adversely impact the business and securities offerings.
• The company is subject to risks associated with the Holding Foreign Companies Accountable Act (HFCA Act), which could lead to the delisting of its shares from U.S. stock exchanges if the Public Company Accounting Oversight Board (PCAOB) is unable to inspect its auditors for three consecutive years.
• Nasdaq may apply additional and more stringent criteria for continued listing, and a proposed new $5 million minimum market value continued listing requirement could result in immediate delisting.
• The company operates in a highly competitive market, and failure to compete effectively could adversely affect its results.
• Perceived adverse effects on human health linked to the consumption of food derived from animals that utilize the company's products could cause a decline in sales.
• Increased regulation relating to the raising, processing, or consumption of food-producing animals could reduce demand for the company's livestock products.
• The company's business is subject to risk based on customer exposure to rising costs and reduced customer income.
• The company's research and development, acquisition, and licensing efforts may fail to generate new products and brand life-cycle developments.
• Manufacturing problems may cause product launch delays, inventory shortages, recalls, or unanticipated costs.
• The company derives a significant portion of its revenue from swine vaccines, and any reduction in demand could have an adverse effect on its business.
• The company's business is subject to inherent risks relating to product liability, and it currently does not have sufficient product liability insurance.
• The company's business will be materially and adversely affected if its collaborative partners, licensees, and other third parties over whom it is dependent fail to perform as expected.
• The company's business requires a number of permits and licenses, and there is no assurance that it can maintain all required licenses, permits, and certifications.
• The company's ability to generate more revenue would be adversely affected if it needs more clinical trials or takes more time to complete them than planned.
• If the company cannot retain, attract, and motivate key personnel, it may be unable to effectively implement its business plan.
• If the company is unable to obtain the regulatory approvals or clearances necessary to commercialize its products, it will have less revenue than expected.
• The company sources its raw materials from a limited number of suppliers, and losing one or more suppliers could disrupt its operations.
• High customer concentration exposes the company to risks faced by its major customers and may subject it to significant fluctuations or declines in revenue.
• Damage to the company's brand image could have a material adverse effect on its growth strategy and business.
• If the company cannot successfully protect its intellectual property and exclusive rights, its brand and business would suffer.
• The company may be accused of infringing, misappropriating, or otherwise violating the intellectual property rights of third parties.
• The company is subject to legal and regulatory proceedings from time to time in the ordinary course of its business.
• The company could be adversely affected by violations of the U.S. Foreign Corrupt Practices Act and similar worldwide anti-bribery laws.
• The company's dual-class share structure with different voting rights may adversely affect the value and liquidity of the Class A Ordinary Shares and limit shareholders' ability to influence corporate matters.
• Future issuances of Class B Ordinary Shares may be dilutive to holders of Class A Ordinary Shares and could further concentrate voting power.
• The company may fail to implement and maintain an effective system of internal controls or fail to remediate material weaknesses, which could result in failure to meet reporting obligations or prevent fraud.
• The company incurred substantial increased costs as a result of being a public company.
• The market price of the company's Class A Ordinary Shares may be volatile or may decline regardless of its operating performance, and shareholders may not be able to resell their shares at or above the initial public offering price.
• The company's management has broad discretion to determine how to use the funds raised in the offering and may use them in ways that may not enhance its results of operations or the price of its Class A Ordinary Shares.
• If the company ceases to qualify as a foreign private issuer, it would incur significant additional legal, accounting, and other expenses.
• As a foreign private issuer, the company is exempt from certain Nasdaq corporate governance standards, which may afford less protection to investors.
• If the company cannot continue to satisfy the listing requirements and other rules of Nasdaq, its securities may be delisted, which could negatively impact their price and liquidity.
• The company is an exempted company incorporated under the laws of the Cayman Islands, and Cayman Islands law may not provide shareholders with benefits comparable to those provided to shareholders of corporations incorporated in the United States.
• The company's business is subject to seasonality, with demand for veterinary products increasing during colder seasons due to weakened animal immunity and increased prevalence of diseases.

Future Outlook

The company intends to develop high-demand products, expand its sales and distribution network both domestically and internationally, enhance its ability to attract and retain talented professionals, and advance merger and acquisition initiatives, particularly in the pet sector.

Management Comments

• Management believes that the amount of available cash balance as of December 31, 2025 and forecasted net cash flows for a period of one year after the issuance of the consolidated financial statements will be sufficient for the Company to satisfy its obligations and commitments when they become due.
• Management believes that the company offers its employees competitive compensation packages and an environment that encourages self-development and, as a result, has generally been able to attract and retain qualified personnel and maintain a stable core management team.

Industry Context

StockSavvy.ai notes that the significant revenue decline and net loss reported by Zhengye Biotechnology Holding Limited in fiscal year 2025 reflect challenges within the veterinary vaccine market, particularly the impact of market downturns and government policies on the swine sector. The company's strategic shift towards household animal vaccines and expansion into new markets are key initiatives to mitigate these pressures and drive future growth.

Comparison to Industry Standards

• The company's revenue decline in 2025 is a significant deviation from the growth observed in previous years, indicating a challenging market environment for swine vaccines.
• The increase in R&D expenses as a percentage of revenue suggests a strategic focus on product diversification and innovation, which is a common strategy in the competitive biotechnology sector.
• The company's gross profit margin decline from 49.0% to 20.5% is a notable negative trend, potentially impacting profitability and requiring cost management strategies.

Corporate Governance

Legal Proceedings

• As of the date of this annual report, neither the company nor its operating entity is a party to any material legal or administrative proceedings.
• The company may be subject to various claims and legal actions arising in the ordinary course of business, but believes that any ultimate liability will not have a material adverse effect on its consolidated financial position, results of operations, or liquidity.

Related Party Transactions

• For the year ended December 31, 2025, the operating entity purchased venue and catering services from Beijing Hanzhenyuan (controlled by a shareholder) for RMB746,000 (US$107,000).
• For the year ended December 31, 2025, the operating entity provided a working capital loan of RMB7,000,000 (US$1,001,000) to Jilin Huazheng (controlled by Mr. Zhenfa Han), which was fully repaid.
• For the years ended December 31, 2023, 2024, and 2025, the operating entity purchased goods from Jilin Huazheng in the amounts of RMB127,000, RMB119,000, and RMB127,000 (US$18,000), respectively.
• For the year ended December 31, 2024, the company obtained a working capital loan of RMB146,000 (US$20,000) from Jiahe Developments Limited (controlled by Mr. Zhenfa Han), which was fully repaid in January 2025.

Stakeholder Impact

• Shareholders may experience reduced value and liquidity of Class A Ordinary Shares due to the dual-class share structure.
• Investors may face challenges in protecting their interests due to Cayman Islands law potentially offering less protection than U.S. jurisdictions.
• The company's financial performance and stock price could be adversely affected by regulatory actions in China or the U.S., or by geopolitical tensions between the U.S. and China.
• The material weakness in internal controls could lead to a loss of investor confidence and negatively impact the market price of Class A Ordinary Shares.

Next Steps

• Develop high-demand products and expand into the household animal vaccines industry.
• Expand sales and distribution network domestically and internationally.
• Enhance ability to attract, incentivize, and retain talented professionals.
• Advance merger and acquisition initiatives in the pet sector in 2026.
• Address the material weakness in internal control over financial reporting by recruiting qualified accounting personnel and implementing training programs.

Key Dates

Recommendation

The company's significant revenue decline, shift to a net loss, widening operating loss, and identified material weakness in internal controls indicate a deteriorating financial performance and increased operational risk. While the company is pursuing strategic initiatives for future growth, the current financial health and control environment suggest a negative outlook for investors in the short to medium term.

Keywords

Zhengye Biotechnology, Form 20-F, Annual Report, Veterinary Vaccines, Livestock Vaccines, Swine Vaccines, Poultry Vaccines, Animal Health, China, Nasdaq, SEC Filing, Financial Results, Revenue Decline, Net Loss, R&D Expenses, Corporate Governance, Share Reclassification, Dual-Class Share Structure